Coral Laboratories Limited manufactures and sells pharmaceutical formulations in India, Ethiopia, and internationally. The company offers non-sterile products, including antibiotics/antibacterial, antifungal, gastro-intestinal drugs, antiemetic, analgesics/antipyretic/anti-inflammatory, antispasmodic, muscle relaxants, cough suppressant/expectorant, anticold, antiallergic, anti-asthmatic, cardiovascular medicines, anti-diabetic, anthelmentic, anti-protozoal/anti-amebic, antimalarial drugs, antipsychotic drugs, and thyroid products; topical, oral antiseptic, and calcium preparations; mouthwashes; nutritional, protein, and iron supplements; kits; appetizers; and other products. It also provides sterile products, such as small volume liquid, cephalosporin, betalactam, and lyophilized injectables; eye, ear, and nose drops; nasal sprays and metered dose inhalers; and large volume parenteral. In addition, the company offers various nutraceutical products, such as dietary supplements, herbal/
| Current Price | ₹506.30 |
|---|---|
| Market Cap | ₹181 Cr |
| Sector | Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals |
| Sub-Industry | Pharmaceuticals > Medicinal Chemicals and Botanical Products |
| P/E Ratio | 11 |
| Return on Equity | 7.99% |
| 52-Week Range | ₹360.00 – ₹624.95 |
| Beta (1Y) | 0.56 |
| Dividend Yield | 0.40% |
Coral Laboratories Ltd. is trading at ₹506.30, with a market capitalisation of ₹181 Cr.
Coral Laboratories Ltd. operates in the Health Care > Pharmaceuticals, Biotechnology and Life Sciences > Pharmaceuticals space (Pharmaceuticals > Medicinal Chemicals and Botanical Products).
Coral Laboratories Ltd. has a P/E of 11 and a return on equity of 7.99%.